Exploiting PrP for the diagnosis and treatment of protein aggregation diseases

利用 PrP 诊断和治疗蛋白质聚集疾病

• 批准号: 9134652
• 负责人: Dominic Martin Walsh
• 金额: $ 27.13万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9134652
• 关键词: Affect; Affinity; Agreement; Alanine; Alzheimer' s Disease; American; Amino Acid Sequence; Amino Acids; Amyloid; Amyloid beta-Protein; Antibodies; Attention; Binding; Binding Proteins; Binding Sites; Biological Assay; Brain; Clinical; Data; Detection; Diagnosis; Diagnostic; Disease; Engineering; Event; Frontotemporal Dementia; Generations; Goals; Health; Human; Immunoassay; Immunoglobulin G; In Vitro; Lead; Length; Libraries; Measures; Mediating; Medical; Molecular; Molecular Conformation; Mus; Mutagenesis; Mutation; N-terminal; Nerve Degeneration; Neurodegenerative Disorders; Neurons; Parkinson Disease; Peptide Sequence Determination; Peptides; Phase; Population; PrP; Prion Diseases; Prions; Process; Property; Proteins; Public Health; Publishing; Reagent; Recombinant Antibody; Recombinant Proteins; Recombinants; Research; Sampling; Scanning; Shapes; Site; Solid; Specificity; Stretching; Surface Plasmon Resonance; Testing; Therapeutic; Toxic effect; Transplantation; alpha synuclein; base; chimeric antibody; complementarity-determining region 3; conformer; design; effective therapy; improved; inhibitor/antagonist; interest; monomer; nanomolar; nervous system disorder; neurotoxicity; novel; polypeptide; prevent; protein aggregation; protein oligomer; receptor; tau Proteins; tau aggregation; therapeutic target; tool; yeast prion

DESCRIPTION (provided by applicant): Neurodegenerative diseases are a major public health problem that affects tens of millions of Americans and compelling evidence indicates that oligomerization and fibrillization of specific proteins is a common facet of almost all such disorders. Two of the most widely studied proteins involved in neurodegeneration are the prion protein (PrP) and the amyloid b-protein (Ab). Amid controversy, provocative data have emerged which suggest that PrP may serve as a receptor that mediates Ab toxicity. While the pathological significance of Ab binding to PrP remains contentious, there is complete agreement that PrP binds Ab oligomers with high affinity and that PrP is a sub-stoichiometric inhibitor of Ab aggregation. Agents with such properties have potential for use in both the diagnosis and treatment of Alzheimer's disease, but until now efforts to target and detect disease- associated protein oligomers have largely depended on the use of antibodies. Based on our demonstration that PrP is superior to lead conformation-specific antibodies in terms of affinity, specificity and anti-aggregation activity, we propose to exploit PrP to generate highly potent anti-oligomer reagents. However, little is known about the molecular basis that underlies PrP's ability to bind Ab oligomers and prevent the aggregation of Ab monomer. Therefore, we propose to identify the amino acids in PrP that are involved in the recognition of Ab and to modify these to further enhance PrP's ability to bind Ab oligomers and inhibit Ab aggregation. Two stretches of sequence within PrP are implicated in oligomer binding and we will focus our efforts on these. Identification of the key residues and further optimization of PrP's binding to Ab oligomers will be achieved by an iterative process of introducing "design mutations" in these two sites. At each step we will test if the mutagenized PrP can bind to Ab oligomers or prevent Ab aggregation. This approach should produce a recombinant PrP derivative - a 'super-binder' that can be used for both the quantification and the targeting of toxic Ab oligomers. However, the potential uses of PrP derivatives may go beyond Alzheimer's disease. Since PrP is known to bind oligomeric forms of certain designed b-sheet-rich peptides, we hypothesize that PrP will be capable of binding to other protein oligomers. Consequently we will investigate if PrP can bind to oligomers and/or prevent the aggregation of a-synuclein which is associated with Parkinson's disease, and of tau which is associated with frontotemporal dementia. In so doing, we will determine whether PrP's activity is specific for Ab or is a property that extends to other key disease-implicated protein oligomers. We will also transplant sequences from the two PrP oligomer-binding sites into an IgG to produce a unique type of chimeric antibody and test if this antibody can recognize and protect against Ab oligomers isolated from human brain. Finally, we will generate additional antibodies containing PrP sequences we optimize in our PrP mutagenesis studies and test these against a-synuclein and tau oligomers. In this way we will generate new tools to detect and neutralize toxic oligomers centrally implicated in human neurodegeneration.

描述（由申请人提供）：神经退行性疾病是影响数千万美国人的主要公共卫生问题，令人信服的证据表明，特定蛋白质的寡聚化和纤维化是几乎所有此类疾病的共同方面。朊蛋白（PrP）和淀粉样蛋白b （Ab）是两种被广泛研究的与神经变性有关的蛋白质。在争议中，已经出现了具有挑衅性的数据，表明PrP可能作为介导Ab毒性的受体。虽然Ab与PrP结合的病理意义仍有争议，但完全一致的是，PrP与Ab低聚物具有高亲和力，并且PrP是Ab的亚化学计量抑制剂

项目成果

Soluble Aβ aggregates can inhibit prion propagation.

• DOI: 10.1098/rsob.170158
• 发表时间: 2017-11
• 期刊: Open biology
• 影响因子: 5.8
• 作者: Sarell CJ;Quarterman E;Yip DC;Terry C;Nicoll AJ;Wadsworth JDF;Farrow MA;Walsh DM;Collinge J
• 通讯作者: Collinge J